VIR News and Press, Vir Biotechnology Inc. From 02/28/22

Vir Biotechnology (VIR -9.0%) the maker of COVID-19 antibody therapy sotrovimab is trading lower for the second consecutive session on Monday. Aside from the general weakness in the market, the recent decline in COVID-19 cases and hospitalizations appeared to have led to the recent selloff. &...

100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...

Vir Biotechnology press release (NASDAQ:VIR): Q4 GAAP EPS of $3.92 beats by $1.29. Revenue of $812.7M (+46876.9% Y/Y) beats by $189.8M. Cash, Cash Equivalents and Investments: As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5M in cash, cash equivalents, ...

– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – – Multiple commercial and clinical va...

The U.S. Food and Drug Administration noted that  GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology's (NASDAQ:VIR) coronavirus antibody therapy should not be used in areas with circulation of variants which are not susceptible to the drug, Reuters reported. Earlier in February,  GSK ...

Vir's prospects depend entirely on the SARS-COV2 virus and emerging variants, if any. Here I discuss a set of option strategies to hedge against various scenarios. I must note that Vir has provided excellent returns to me last year. For further details see: Vir Biotechno...

Vir Biotechnology and GlaxoSmithKline expect to develop 2 million doses of Covid-19 antiviral Sotrovimab in the 1st half of 2022, with more to follow in the 2nd half of 2022. An Emergency Use Authorization of Sotrovimab has been filed as an intramuscular injection for patients with mi...

3 Top Health Care Stocks To Watch Right Now As the stock market continues to show volatility, some investors may flock to more defensive stocks such as health care stocks . Admittedly, the current global pandemic does influence the sentiment around the health care sector. Howeve...

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022. The update will...

The stock market is giving investors some real healthcare bargains right now. In this Fool.com roundtable, we present bullish views on a couple of NASH stocks that have been hammered. And we give some love to an under-the-radar COVID play that is super cheap right now. Here's why our te...